Teva Pharma is expected to report Q2 2026 consensus revenue of $4.07 billion and non-GAAP EPS of $0.41, with its stock currently trading at $30.81, significantly below the $41.78 average analyst price target.
Investors are primarily focused on the sales growth of the tardive dyskinesia treatment Austedo, a central pillar of the company's "Pivot to Growth" strategy as it nears blockbuster status.
While overall results are expected to show a year-over-year decline due to generic Revlimid competition and dilution from the Emalex Biosciences acquisition, the focus remains on high-margin innovative expansion. Analysts will also look for debt reduction progress and clinical updates for late-stage pipeline assets like duvakitug and ecopipam.